Cell line-derived xenograft (CDX) models are a cornerstone of oncology drug development, offering a robust and reproducible platform to evaluate the in vivo efficacy of anti-cancer therapies. By implanting well-characterized human tumor cell lines into immunocompromised mice, CDX models allow researchers to assess tumor growth inhibition, dosing strategies, and preliminary pharmacodynamic responses in a controlled and scalable system. These models are particularly valuable for early-stage screening and proof-of-concept studies due to their consistency and ease of use. MuriPhys is well equipped to support CDX studies with dedicated expertise in tumor implantation (subcutaneous, orthotopic), precise IV/IM/SC drug administration, and longitudinal tumor monitoring using caliper measurements and advanced in vivo imaging. Our experienced team, specialized facilities, and commitment to scientific rigor make MuriPhys an ideal partner for conducting high-quality CDX studies that advance oncology pipelines toward the clinic.
Below is a list of available models commonly used by MuriPhys researchers:
Solid Tumor Xenograft Models
Brest Cancer
MDA-MB-231 (TNBC, highly metastatic)
MCF-7 (ER+, PR+, luminal A subtype)
T47D (ER+, PR+, luminal B subtype)
Non-Small Cell Lung Cancer (NSCLC)
A549 (KRAS mutant, adenocarcinoma)
H1975 (EGFR T790M mutant, resistant to 1st-gen TKIs)
H1299 (p53-null, metastatic potential)
Colorectal Cancer
HCT116 (KRAS mutant, MSI+)
SW620 (metastatic colorectal cancer model)
HT-29 (BRAF V600E mutant, chemoresistant)
Pancreatic Cancer
PANC-1 (KRAS mutant, mesenchymal phenotype)
MiaPaCa-2 (KRAS mutant, p53 mutant, highly aggressive)
AsPC-1 (metastatic potential)
Brain Tumor
U87MG (glioblastoma, limited invasion capacity)
U251 (astrocytoma-derived, high proliferation)
DAOY (medulloblastoma, pediatric brain cancer)
Prostate Cancer
LNCaP (androgen-sensitive, PSA-producing)
DU145 (androgen-independent, metastatic potential)
PC-3 (highly aggressive, androgen receptor-negative)
Hematologic Cancer Xenograft Models
Leukemia Xenograft Models
Acute Myeloid Leukemia (AML)
- MV4-11 (FLT3-ITD mutant)
- HL-60 (differentiation-sensitive, ATRA-responsive)
- KG-1 (primitive leukemic stem cell-like)
Acute Lymphoblastic Leukemia (ALL)
- Nalm-6 (B-ALL, p53 wild-type)
- MOLT-4 (T-ALL, highly proliferative)
Chronic Myeloid Leukemia (CML)
- K562 (BCR-ABL1 fusion, imatinib-sensitive)
Lymphoma Xenograft Models
Diffuse Large B-Cell Lymphoma (DLBCL)
- SU-DHL-4 (ABC subtype, NF-κB pathway activation)
- OCI-LY3 (activated B-cell-like, MYD88 mutant)
Hodgkin Lymphoma (HL) Models
- L428 (classical HL, CD30+)
- KM-H2 (brentuximab vedotin-sensitive)
Multiple Myeloma Xenograft Models
- MI-8226 (bortezomib-sensitive, IgG lambda secretion)
Advanced Drug Administration & Serial Injections
We specialize in the following routes of administration:
Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), Intrathecal (IT), Intra Peritoneal (IP), Oral Gavage (PO), Topical, Slow-infusion and Continuous Infusions – supporting accurate systemic or localized therapeutic exposure.
Serial Injections – Enabling longitudinal drug administration studies to monitor treatment effects over time.
Quality Control: Mycoplasma Testing
Cell-line quality control includes mycoplasma testing to identify contamination. The testing plan, cell identity checks and acceptance criteria are defined for the study and documented with the work.
At MuriPhys, we are dedicated to accelerating oncology drug discovery with specialized preclinical solutions. Contact us today to discuss how we can support your oncology research!
Discuss the tumor model, treatment strategy, readouts and study stage with our oncology team. We will work with you to define the methods, controls, deliverables, timing and budget.